MYL6

Summary

MYL6 (myosin light chain 6, HGNC:7587) is a protein-coding gene on chromosome 12q13.2, encoding Myosin light polypeptide 6 (P60660). Regulatory light chain of myosin.

Myosin is a hexameric ATPase cellular motor protein. It is composed of two heavy chains, two nonphosphorylatable alkali light chains, and two phosphorylatable regulatory light chains. This gene encodes a myosin alkali light chain that is expressed in smooth muscle and non-muscle tissues. Genomic sequences representing several pseudogenes have been described and two transcript variants encoding different isoforms have been identified for this gene.

Source: NCBI Gene 4637 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 24 total
• Druggable target: yes
• MANE Select transcript: NM_021019

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7587
Approved symbol	MYL6
Name	myosin light chain 6
Location	12q13.2
Locus type	gene with protein product
Status	Approved
Aliases	ESMLC, MLC3NM, MLC1SM
Ensembl gene	ENSG00000092841
Ensembl biotype	protein_coding
OMIM	609931
Entrez	4637

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 18 protein_coding, 4 retained_intron, 3 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000293422, ENST00000348108, ENST00000536128, ENST00000546630, ENST00000546845, ENST00000547408, ENST00000547649, ENST00000547703, ENST00000548293, ENST00000548400, ENST00000548580, ENST00000548725, ENST00000549017, ENST00000549392, ENST00000549566, ENST00000550184, ENST00000550639, ENST00000550697, ENST00000551589, ENST00000551954, ENST00000552297, ENST00000864437, ENST00000864438, ENST00000940642, ENST00000958400, ENST00000958401

RefSeq mRNA: 2 — MANE Select: NM_021019 NM_021019, NM_079423

CCDS: CCDS31834, CCDS8906

Canonical transcript exons

ENST00000550697 — 7 exons

Exon	Start	End
ENSE00002350109	56158359	56158404
ENSE00003498225	56161387	56161579
ENSE00003511540	56158684	56158711
ENSE00003536787	56159587	56159730
ENSE00003563173	56159975	56160148
ENSE00003669360	56160626	56160670
ENSE00003785680	56160243	56160320

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 99.95.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 374.8727 / max 3663.4292, expressed in 1828 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
126078	371.2928	1828
126081	1.1100	545
126079	1.1020	432
126082	1.0415	639
206743	0.2241	93
126080	0.1022	35

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
popliteal artery	UBERON:0002250	99.95	gold quality
tibial artery	UBERON:0007610	99.95	gold quality
lower esophagus	UBERON:0013473	99.95	gold quality
muscle layer of sigmoid colon	UBERON:0035805	99.95	gold quality
lower esophagus muscularis layer	UBERON:0035833	99.95	gold quality
left coronary artery	UBERON:0001626	99.94	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	99.94	gold quality
ascending aorta	UBERON:0001496	99.93	gold quality
thoracic aorta	UBERON:0001515	99.93	gold quality
right coronary artery	UBERON:0001625	99.93	gold quality
mucosa of stomach	UBERON:0001199	99.92	gold quality
descending thoracic aorta	UBERON:0002345	99.92	gold quality
mucosa of transverse colon	UBERON:0004991	99.92	gold quality
stromal cell of endometrium	CL:0002255	99.90	gold quality
upper lobe of left lung	UBERON:0008952	99.90	gold quality
body of uterus	UBERON:0009853	99.90	gold quality
metanephros cortex	UBERON:0010533	99.90	gold quality
colonic epithelium	UBERON:0000397	99.89	gold quality
rectum	UBERON:0001052	99.89	gold quality
transverse colon	UBERON:0001157	99.89	gold quality
left uterine tube	UBERON:0001303	99.89	gold quality
right lung	UBERON:0002167	99.88	gold quality
aorta	UBERON:0000947	99.86	gold quality
right lobe of thyroid gland	UBERON:0001119	99.86	gold quality
right adrenal gland	UBERON:0001233	99.86	gold quality
monocyte	CL:0000576	99.85	gold quality
left lobe of thyroid gland	UBERON:0001120	99.85	gold quality
right adrenal gland cortex	UBERON:0035827	99.85	gold quality
left adrenal gland	UBERON:0001234	99.83	gold quality
calcaneal tendon	UBERON:0003701	99.83	gold quality

Single-cell (SCXA)

Detected in 38 experiment(s), a significant marker in 20.

Experiment	Marker?	Max mean expression
E-HCAD-23	yes	8356.93
E-HCAD-11	yes	6156.61
E-MTAB-10287	yes	5853.45
E-MTAB-8381	yes	5229.17
E-GEOD-111727	yes	2526.59
E-HCAD-9	yes	2021.64
E-HCAD-4	yes	95.63
E-HCAD-1	yes	83.19
E-CURD-122	yes	72.58
E-MTAB-8410	yes	36.35
E-GEOD-134144	yes	32.22
E-MTAB-6678	yes	28.68
E-CURD-46	yes	28.36
E-GEOD-130148	yes	24.43
E-MTAB-9221	yes	21.75

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

10 targeting MYL6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9718	99.94	68.91	918
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-5002-5P	99.76	70.84	1763
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-5584-5P	99.49	68.22	2814
HSA-MIR-377-3P	99.37	70.18	1905
HSA-MIR-628-5P	98.36	67.74	844
HSA-MIR-3157-5P	97.41	67.61	998

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	myl6	ENSDARG00000008494
danio_rerio	zgc:153867	ENSDARG00000033738
rattus_norvegicus	Myl6	ENSRNOG00000054140
drosophila_melanogaster	Mlc-c	FBGN0004687
caenorhabditis_elegans		WBGENE00010554
caenorhabditis_elegans		WBGENE00011734

Paralogs (4): MYL3 (ENSG00000160808), MYL1 (ENSG00000168530), MYL6B (ENSG00000196465), MYL4 (ENSG00000198336)

Protein

Protein identifiers

Myosin light polypeptide 6 — P60660 (reviewed: P60660)

Alternative names: 17 kDa myosin light chain, Myosin light chain 3, Myosin light chain alkali 3, Smooth muscle and nonmuscle myosin light chain alkali 6

All UniProt accessions (12): P60660, B7Z6Z4, F8VPF3, F8VXL3, F8VZU9, F8W180, F8W1R7, G3V1V0, G3V1Y7, G8JLA2, H0YI43, J3KND3

UniProt curated annotations — full annotation on UniProt →

Function. Regulatory light chain of myosin. Does not bind calcium.

Subunit / interactions. Myosin is a hexamer of 2 heavy chains and 4 light chains. Interacts with SPATA6.

Isoforms (2)

UniProt ID	Names	Canonical?
P60660-1	Non-muscle, MLC3nm, LC17A, LC17-nm	yes
P60660-2	Smooth muscle, MLC3sm, LC17B, LC17-sm

RefSeq proteins (2): NP_066299, NP_524147 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002048	EF_hand_dom	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR050230	CALM/Myosin/TropC-like	Family

UniProt features (15 total): modified residue 4, sequence conflict 3, domain 3, sequence variant 2, initiator methionine 1, chain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P60660-F1	95.39	0.97

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 135, 2, 57, 81

Function

Pathways and Gene Ontology

Reactome pathways

18 pathways

ID	Pathway
R-HSA-3928663	EPHA-mediated growth cone collapse
R-HSA-416572	Sema4D induced cell migration and growth-cone collapse
R-HSA-445355	Smooth Muscle Contraction
R-HSA-5625740	RHO GTPases activate PKNs
R-HSA-5625900	RHO GTPases activate CIT
R-HSA-5627117	RHO GTPases Activate ROCKs
R-HSA-5627123	RHO GTPases activate PAKs
R-HSA-1266738	Developmental Biology
R-HSA-162582	Signal Transduction
R-HSA-194315	Signaling by Rho GTPases
R-HSA-195258	RHO GTPase Effectors
R-HSA-2682334	EPH-Ephrin signaling
R-HSA-373755	Semaphorin interactions
R-HSA-397014	Muscle contraction
R-HSA-400685	Sema4D in semaphorin signaling
R-HSA-422475	Axon guidance
R-HSA-9675108	Nervous system development
R-HSA-9716542	Signaling by Rho GTPases, Miro GTPases and RHOBTB3

MSigDB gene sets: 247 (showing top): ATF_B, TGGTGCT_MIR29A_MIR29B_MIR29C, GOBP_MUSCLE_TISSUE_DEVELOPMENT, MODULE_151, KAAB_HEART_ATRIUM_VS_VENTRICLE_UP, SRF_Q5_01, CREB_Q4, SRF_01, SRF_C, GOBP_MUSCLE_STRUCTURE_DEVELOPMENT, GOBP_MUSCLE_CONTRACTION, MODULE_202, GOMF_CYTOSKELETAL_MOTOR_ACTIVITY, GOBP_SKELETAL_MUSCLE_ORGAN_DEVELOPMENT, ATF3_Q6

GO Biological Process (3): muscle contraction (GO:0006936), skeletal muscle tissue development (GO:0007519), muscle filament sliding (GO:0030049)

GO Molecular Function (5): microfilament motor activity (GO:0000146), cytoskeletal motor activity (GO:0003774), calcium ion binding (GO:0005509), structural constituent of muscle (GO:0008307), protein binding (GO:0005515)

GO Cellular Component (8): cytosol (GO:0005829), brush border (GO:0005903), membrane (GO:0016020), myosin complex (GO:0016459), myosin II complex (GO:0016460), unconventional myosin complex (GO:0016461), vesicle (GO:0031982), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-11 pathways:

Category	Pathways
RHO GTPase Effectors	4
Axon guidance	2
EPH-Ephrin signaling	1
Sema4D in semaphorin signaling	1
Muscle contraction	1
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1
Signaling by Rho GTPases	1
Semaphorin interactions	1
Nervous system development	1
Developmental Biology	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
myosin complex	2
muscle system process	1
striated muscle tissue development	1
skeletal muscle organ development	1
muscle contraction	1
actin-myosin filament sliding	1
cytoskeletal motor activity	1
polypeptide conformation or assembly isomerase activity	1
ATP-dependent activity	1
molecular_function	1
metal ion binding	1
structural molecule activity	1
binding	1
cytoplasm	1
microvillus	1
apical part of cell	1
cluster of actin-based cell projections	1
actin cytoskeleton	1
protein-containing complex	1
membrane-bounded organelle	1
extracellular vesicle	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

206 interactions, top by confidence:

A	B	Type	Score
NS	PIK3R2	psi-mi:“MI:0914”(association)	0.750
NUDT21	MYL6	psi-mi:“MI:0915”(physical association)	0.740
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
MYL6	ADAMTS12	psi-mi:“MI:0915”(physical association)	0.670
ADAMTS12	MYL6	psi-mi:“MI:0915”(physical association)	0.670
RAC1	COX6C	psi-mi:“MI:0914”(association)	0.640
ESR1	MYL6	psi-mi:“MI:0407”(direct interaction)	0.640
MYH9	MYL12B	psi-mi:“MI:0914”(association)	0.640
MYL6	MYH9	psi-mi:“MI:0914”(association)	0.640
MYL6	GAS2L3	psi-mi:“MI:0915”(physical association)	0.560
GAS2L3	MYL6	psi-mi:“MI:0915”(physical association)	0.560
MYL6	DDIT4L	psi-mi:“MI:0915”(physical association)	0.560
MYL6	AGR2	psi-mi:“MI:0915”(physical association)	0.560
AGR2	MYL6	psi-mi:“MI:0915”(physical association)	0.560
ZNF195	BAG2	psi-mi:“MI:0914”(association)	0.530

BioGRID (366): ADAMTS12 (Two-hybrid), MYL6 (Affinity Capture-MS), NUDT21 (Two-hybrid), MYL6 (Two-hybrid), MYL6 (Affinity Capture-MS), AHCYL1 (Co-fractionation), AHNAK (Co-fractionation), CYC1 (Co-fractionation), MYL6 (Co-fractionation), MYL6 (Co-fractionation), MYL6 (Co-fractionation), MYL6 (Co-fractionation), RAB2A (Co-fractionation), STMN1 (Co-fractionation), TPM2 (Co-fractionation)

ESM2 similar proteins: A0A1S4A695, A0PJX0, A2VE08, B1H2N3, C7A278, O70133, P02607, P05044, P05943, P08207, P16905, P27003, P43246, P43247, P52294, P54275, P60660, P60661, P60662, P83953, Q17QE5, Q1W374, Q1W375, Q1W376, Q1W377, Q259G4, Q3MHE4, Q3T0E8, Q4R518, Q503E9, Q5R844, Q5R909, Q5XXB5, Q5ZKU1, Q5ZML1, Q60605, Q60960, Q64119, Q68FK8, Q6P069

Diamond homologs: A0JNJ5, A2Y609, A3E3H0, A3E4D8, A3E4F9, A4UHC0, A8CEP3, A8I1Q0, F1RRT2, J7HCX7, O14008, O60041, O82018, O94739, P02597, P02598, P02600, P02602, P02604, P02605, P02606, P02607, P04353, P04464, P05419, P05976, P05977, P06742, P06787, P07290, P07291, P07462, P07463, P08053, P08590, P09540, P09541, P09542, P0DH95, P0DH96

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 184 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RHO GTPases activate PAKs	8	33.7×	4e-08
RHO GTPases activate CIT	6	28.0×	5e-06
Signaling by ERBB2 ECD mutants	5	26.0×	5e-05
GRB2 events in ERBB2 signaling	5	24.6×	5e-05
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	6	24.1×	8e-06
Tie2 Signaling	5	23.3×	6e-05
RHO GTPases Activate ROCKs	5	23.3×	6e-05
FCERI mediated MAPK activation	7	18.8×	6e-06

GO biological processes:

GO term	Partners	Fold	FDR
actin filament-based movement	5	25.2×	7e-04
mRNA stabilization	6	13.8×	1e-03
substantia nigra development	5	11.5×	8e-03
Ras protein signal transduction	8	10.3×	7e-04
positive regulation of cell differentiation	6	10.1×	4e-03
response to ethanol	7	6.5×	9e-03
negative regulation of gene expression	10	4.3×	9e-03
positive regulation of gene expression	15	3.6×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

24 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	12
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1123 predictions. Top by Δscore:

Variant	Effect	Δscore
12:56158712:G:GA	donor_loss	1.0000
12:56159576:T:TA	acceptor_gain	1.0000
12:56159786:C:G	donor_gain	1.0000
12:56159968:AT:A	acceptor_gain	1.0000
12:56159969:T:G	acceptor_gain	1.0000
12:56159969:T:TA	acceptor_gain	1.0000
12:56159970:GGCAG:G	acceptor_loss	1.0000
12:56159971:GCA:G	acceptor_loss	1.0000
12:56159972:CA:C	acceptor_loss	1.0000
12:56159973:A:AG	acceptor_gain	1.0000
12:56159973:A:C	acceptor_loss	1.0000
12:56159974:G:GG	acceptor_gain	1.0000
12:56159974:GA:G	acceptor_gain	1.0000
12:56159974:GAGA:G	acceptor_gain	1.0000
12:56159974:GAGAT:G	acceptor_gain	1.0000
12:56160094:G:GT	donor_gain	1.0000
12:56160095:A:T	donor_gain	1.0000
12:56160130:C:T	donor_gain	1.0000
12:56160144:ACTGG:A	donor_gain	1.0000
12:56160146:TGGGT:T	donor_loss	1.0000
12:56160147:GG:G	donor_gain	1.0000
12:56160148:GG:G	donor_gain	1.0000
12:56160149:G:GA	donor_loss	1.0000
12:56160149:G:GG	donor_gain	1.0000
12:56160150:T:A	donor_loss	1.0000
12:56160238:T:TA	acceptor_gain	1.0000
12:56160241:A:AG	acceptor_gain	1.0000
12:56160241:AG:A	acceptor_gain	1.0000
12:56160241:AGGT:A	acceptor_gain	1.0000
12:56160242:G:A	acceptor_gain	1.0000

AlphaMissense

1010 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:56160085:T:C	F96L	1.000
12:56160087:T:A	F96L	1.000
12:56160087:T:G	F96L	1.000
12:56159601:T:C	F16L	0.999
12:56159603:C:A	F16L	0.999
12:56159603:C:G	F16L	0.999
12:56159610:T:C	F19L	0.999
12:56159612:T:A	F19L	0.999
12:56159612:T:G	F19L	0.999
12:56159665:G:C	R37T	0.999
12:56159665:G:T	R37M	0.999
12:56159666:G:C	R37S	0.999
12:56159666:G:T	R37S	0.999
12:56160073:G:A	G92R	0.999
12:56160073:G:C	G92R	0.999
12:56160077:T:C	L93P	0.999
12:56160110:T:A	V104D	0.999
12:56160137:T:C	L113P	0.999
12:56160243:G:T	G117V	0.999
12:56159602:T:C	F16S	0.998
12:56159608:T:C	L18P	0.998
12:56160008:T:C	F70S	0.998
12:56160020:T:C	L74P	0.998
12:56160074:G:A	G92E	0.998
12:56160077:T:A	L93H	0.998
12:56160086:T:C	F96S	0.998
12:56160088:G:C	D97H	0.998
12:56160089:A:T	D97V	0.998
12:56160137:T:A	L113H	0.998
12:56160148:G:C	G117R	0.998

dbSNP variants (sampled 300 via entrez): RS1000074946 (12:56159333 T>C), RS1000265933 (12:56156421 A>G), RS1001165798 (12:56160690 C>T), RS1001492387 (12:56160547 A>C,G), RS1001728908 (12:56161631 T>C), RS1002175197 (12:56157915 C>A,T), RS1003359827 (12:56157384 C>T), RS1003803310 (12:56160470 G>A,T), RS1004303195 (12:56157630 T>C), RS1005514198 (12:56160458 G>A), RS1006510960 (12:56161585 G>A), RS1006935105 (12:56156690 C>G,T), RS1007146383 (12:56160950 T>A), RS1008430607 (12:56158727 T>C), RS1009252883 (12:56160896 G>A)

Disease associations

OMIM: gene MIM:609931 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST008916_124	Asthma	1.000000e-16

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066273 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.09	Kd	81.48	nM	CHEMBL5653589
7.09	ED50	81.48	nM	CHEMBL5653589
5.24	Kd	5790	nM	CHEMBL3752910
5.24	ED50	5790	nM	CHEMBL3752910

PubChem BioAssay actives

2 with measured affinity, of 4 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148809: Binding affinity to human MYL6 incubated for 45 mins by Kinobead based pull down assay	kd	0.0815	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148809: Binding affinity to human MYL6 incubated for 45 mins by Kinobead based pull down assay	kd	5.7896	uM

CTD chemical–gene interactions

66 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, increases expression, affects expression, affects cotreatment, increases methylation	6
Particulate Matter	decreases expression, increases abundance, affects cotreatment, affects expression, increases expression	4
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	3
Tretinoin	increases expression	3
Air Pollutants	affects cotreatment, increases abundance, increases expression, decreases expression	2
Cisplatin	affects cotreatment, decreases expression, increases expression	2
Doxorubicin	affects expression, increases expression	2
Estradiol	decreases reaction, increases expression, decreases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Cadmium Chloride	increases expression	2
FR900359	increases phosphorylation	1
bisphenol F	increases expression	1
TAK-243	increases sumoylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	increases expression, increases abundance, affects cotreatment	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, decreases expression	1
arsenite	affects binding, increases reaction	1
3,3’-diindolylmethane	decreases reaction, increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
lead chloride	increases expression	1
methacrylaldehyde	increases abundance, affects cotreatment, increases expression	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
dibenzo(a,l)pyrene	increases expression	1
phenethyl isothiocyanate	affects binding	1
pentabromodiphenyl ether	increases expression	1
chloropicrin	increases expression	1
monomethylarsonous acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
clothianidin	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651851	Binding	Binding affinity to human MYL6 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.